Physician profile
William C Cody
NPI 1356390413
$6,319.63
in general payments reported to CMS, 2019-2025
17 companies · $838 in 2025
The $838 reported for 2025 was more than what a typical Colon & Rectal Surgery provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,929 · 2020: $159 · 2021: $254 · 2022: $63.57 · 2023: $1,914 · 2024: $162 · 2025: $838.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,587 · Food and Beverage: $1,327.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,587.01 |
| Food and Beverage | $1,327.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $4,400.05 | 2019-2023 | Da Vinci Surgical System, Da Vinci Sp |
| Medtronic, INC. | $576.83 | 2021-2025 | Endurant Iis, Progrip |
| Davol INC. | $271.25 | 2023-2025 | Phasix Mesh |
| Ethicon US, LLC | $258.12 | 2019-2025 | Vistaseal, Surgicel Nu-Knit |
| Baxter Healthcare | $211.04 | 2025 | Perclot |
| Smith+Nephew, INC. | $127.91 | 2020-2021 | |
| Vertex Pharmaceuticals Incorporated | $124.99 | 2025 | |
| Biocomposites INC | $123.79 | 2025 | Stimulan |
| Kowa Pharmaceuticals America, INC. | $46.14 | 2022-2023 | Seglentis |
| Tela Bio, INC. | $37.62 | 2025 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Acera Surgical, INC. | $28.70 | 2025 | Restrata Wound Matrix |
| Kerecis Limited | $22.69 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide, Kerecis Omega3 Surgiclose |
| Kci USA, INC. | $22.28 | 2023 | V.A.C. Veraflo, Prevena |
| Medtronic Vascular, INC. | $20.42 | 2020 | |
| Integra Lifesciences Corporation | $18.83 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $14.77 | 2022 | |
| Solventum Corporation | $14.20 | 2024 | V.A.C.Ulta, Prevena |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Cody listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.